Payment overview · 2025
General Payments
$868.23
12 reported records · 7 companies
Healthcare provider profile · identity verified
Ratul Chatterjee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTINGTON BEACH, CA · NPI 1770597387
Verified facts
What the public records show
CMS Open Payments records show Ratul Chatterjee, M.D. received $868.23 in general payments during 2025 across 12 reported records.
Aimmune Therapeutics, Inc. accounted for 43.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Prolia, Tymlos.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $374.44 | 43.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $239.52 | 27.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.26 | 14.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $61.11 | 7.0% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $28.05 | 3.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.56 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.29 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $868.23 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $374.44 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.26 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.29 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 81 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
187 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1227 | 348 |
| Losartan Potassium | Losartan Potassium | 656 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 323 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 282 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 277 | 75 |
| Metformin Hcl Er | Metformin Hcl | 260 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 77 |
| Prednisone | Prednisone | 246 | 144 |
| Fluticasone Propionate | Fluticasone Propionate | 245 | 114 |
| Trazodone Hcl | Trazodone Hcl | 244 | 78 |
| Carvedilol | Carvedilol | 232 | 63 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 56 |
| Furosemide | Furosemide | 209 | 69 |
| Gabapentin | Gabapentin | 204 | 55 |
| Eliquis | Apixaban | 193 | 52 |
| Montelukast Sodium | Montelukast Sodium | 189 | 56 |
| Farxiga | Dapagliflozin Propanediol | 187 | 42 |
| Bupropion Xl | Bupropion Hcl | 176 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 173 | 44 |
| Metformin Hcl | Metformin Hcl | 168 | 44 |
| Valsartan | Valsartan | 162 | 43 |
| Lisinopril | Lisinopril | 161 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 161 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 96 |
| Azelastine Hcl | Azelastine Hcl | 156 | 59 |
| Lorazepam | Lorazepam | 153 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 47 |
| Ozempic | Semaglutide | 144 | 29 |
| Alendronate Sodium | Alendronate Sodium | 140 | 44 |
| Azithromycin | Azithromycin | 132 | 105 |
| Tramadol Hcl | Tramadol Hcl | 131 | 39 |
| Alprazolam | Alprazolam | 124 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 29 |
| Finasteride | Finasteride | 118 | 38 |
| Pregabalin | Pregabalin | 118 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 37 |
| Omeprazole | Omeprazole | 116 | 33 |
| Celecoxib | Celecoxib | 112 | 60 |
| Sertraline Hcl | Sertraline Hcl | 110 | 27 |
| Memantine Hcl | Memantine Hcl | 109 | 19 |
| Ezetimibe | Ezetimibe | 100 | 32 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 97 | 32 |
| Clonazepam | Clonazepam | 93 | 24 |
| Meloxicam | Meloxicam | 91 | 46 |
| Allopurinol | Allopurinol | 90 | 24 |
| Aripiprazole | Aripiprazole | 90 | 14 |
| Felodipine Er | Felodipine | 89 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 24 |
| Famotidine | Famotidine | 82 | 25 |
| Mounjaro | Tirzepatide | 81 | 12 |
| Ondansetron Odt | Ondansetron | 80 | 56 |
| Simvastatin | Simvastatin | 80 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 16 |
| Potassium Chloride | Potassium Chloride | 75 | 27 |
| Clonidine Hcl | Clonidine Hcl | 73 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 72 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 19 |
| Atenolol | Atenolol | 59 | 15 |
| Synthroid | Levothyroxine Sodium | 59 | 16 |
| Ibandronate Sodium | Ibandronate Sodium | 56 | 18 |
| Xarelto | Rivaroxaban | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Gemtesa | Vibegron | 52 | 17 |
| Methylphenidate Hcl | Methylphenidate Hcl | 50 | suppressed |
| Cephalexin | Cephalexin | 49 | 39 |
| Solifenacin Succinate | Solifenacin Succinate | 48 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 46 | 20 |
| Temazepam | Temazepam | 45 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 25 |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 44 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 17 |
| Glimepiride | Glimepiride | 43 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Hydrocortisone | Hydrocortisone | 42 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 15 |
| Myrbetriq | Mirabegron | 40 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 15 |
| Lactulose | Lactulose | 37 | 17 |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Irbesartan | Irbesartan | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Jardiance | Empagliflozin | 31 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 27 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Diazepam | Diazepam | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 16 |
| Ketoconazole | Ketoconazole | 25 | 11 |
| Testosterone | Testosterone | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 14 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Prolia | Denosumab | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Tretinoin | Tretinoin | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $868.23 · 12 records | Aimmune Therapeutics, Inc. | AIRSUPRA, BREZTRI, EVENITY, LEQVIO, MOUNJARO, OTEZLA, PROLIA, REPATHA, Tymlos, VOQUEZNA, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error